Impact of low serum hemoglobin on development of contrast-induced nephropathy (CIN) in patients with hepatocellular carcinoma (HCC) following transarterial chemoembolisation (TACE).
Chemoembolization
Contrast-induced nephropathy
Hemoglobin
Hepatocellular carcinoma
Propensity score
therapeutic
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
27
07
2020
accepted:
04
11
2020
pubmed:
5
1
2021
medline:
7
10
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
To assess the association between low hemoglobin (Hb) level and development of contrast-induced nephropathy (CIN) for hepatocellular carcinoma (HCC) patients after transarterial chemoembolization (TACE). A retrospective analysis was performed on 284 patients undergoing 503 consecutive sessions of TACE. Propensity score matching (PSM) analysis was used to reduce the influence of the difference in variables in normal and low hemoglobin groups. Risk factors of CIN were assessed by univariate and multivariate logistic regression analysis. The relation between Hb level and CIN development was analyzed by receiver operating characteristic (ROC) curve. CIN developed in 5.6% patients after TACE. Multivariate logistic regression analysis showed that hypertension, Hb and serum creatinine (Scr) were independent risk factors for the development of post-TACE CIN. Grouped by normal or low Hb, the incidence of CIN was 14.6% (16/110) in the low Hb group and 3.4% (4/116) in the normal Hb group after PSM. Multivariate logistic regression analysis revealed that Hb, lymphocyte count, and neutrophil to lymphocyte ratio (NLR) were independent risk factors for the development of post-TACE CIN. The optimal cut-off point at which the Hb concentration resulted in a high probability of developing CIN was 105.5 g/L in males. Low Hb is an independent risk factor for post-TACE CIN. Therefore, HCC patients with low Hb levels should be closely monitored before and during TACE.
Identifiants
pubmed: 33392886
doi: 10.1007/s11255-020-02712-7
pii: 10.1007/s11255-020-02712-7
doi:
Substances chimiques
Contrast Media
0
Hemoglobins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1189-1195Subventions
Organisme : National Key R&D Development of China Project
ID : 2017YFC0113403
Organisme : National Natural Science Foundation of China
ID : 81571635
Organisme : Binzhou Medical University Research Program and Research Foundation Project
ID : BY2018KJ30
Références
Lufft V, Hoogestraat-Lufft L, Fels LM et al (2002) Contrast media nephropathy: intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis: a prospective randomized trial. Am J Kidney Dis 40:236–242
doi: 10.1053/ajkd.2002.34501
Chou SH, Wang ZJ, Kuo J et al (2011) Persistent renal enhancement after intra-arterial versus intravenous iodixanol administration. Eur J Radiol 80:378–386
doi: 10.1016/j.ejrad.2011.02.044
Huo TI, Wu JC, Huang YH et al (2004) Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Aliment Pharmacol Ther 19:999–1007
doi: 10.1111/j.1365-2036.2004.01936.x
Park J, Chung HC, Lee JS et al (2008) Acute kidney injury after transarterial chemoembolization for hepatocellular carcinoma: a retrospective analysis. Blood Purif 26:454–459
doi: 10.1159/000157322
Cho HS, Seo JW, Kang Y et al (2011) Incidence and risk factors for radiocontrast-induced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. Clin Exp Nephrol 15:714–719
doi: 10.1007/s10157-011-0470-9
Hayakawa K, Tanikake M, Kirishima T et al (2014) The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). Eur Radiol 24:1105–1111
doi: 10.1007/s00330-014-3099-8
Zhou C, Wang R, Ding Y et al (2014) Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma. Int J Clin Exp Pathol 7:2579–2586
pubmed: 24966972
pmcid: 4069907
Lee BC, Liu KL, Lin CL et al (2017) Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: a nationwide population-based cohort study. Eur Radiol 27:4482–4489
doi: 10.1007/s00330-017-4893-x
Hsu CY, Huang YH, Su CW et al (2010) Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int 30:77–84
doi: 10.1111/j.1478-3231.2009.02128.x
Chong E, Poh KK, Liang S et al (2010) Risk factors and clinical outcomes for contrast-induced nephropathy after percutaneous coronary intervention in patients with normal serum creatinine. Ann Acad Med Singap 39:374–380
pubmed: 20535427
Murakami R, Kumita S, Hayashi H et al (2013) Anemia and the risk of contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT. Eur J Radiol 82:e521-524
doi: 10.1016/j.ejrad.2013.06.004
Guo J, Zheng C, Xiao Q et al (2015) Impact of anaemia on lung function and exercise capacity in patients with stable severe chronic obstructive pulmonary disease. BMJ Open 5:e008295
doi: 10.1136/bmjopen-2015-008295
Xu J, Zhang M, Ni Y et al (2016) Impact of low hemoglobin on the development of contrast-induced nephropathy: a retrospective cohort study. Exp Ther Med 12:603–610
doi: 10.3892/etm.2016.3416
van der Molen AJ, Reimer P, Dekkers IA et al (2018a) Post-contrast acute kidney injury—Part 1: definition, clinical features, incidence, role of contrast medium and risk factors: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 28:2845–2855
doi: 10.1007/s00330-017-5246-5
Ruilope LM, Salvetti A, Jamerson K et al (2001) Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 12:218–225
doi: 10.1681/ASN.V122218
Sahin DY, Elbasan Z, Gur M et al (2013) Neutrophil to lymphocyte ratio is associated with the severity of coronary artery disease in patients with ST-segment elevation myocardial infarction. Angiology 64:423–429
doi: 10.1177/0003319712453305
Lim C, Audureau E, Salloum C et al (2016) Acute kidney injury following hepatectomy for hepatocellular carcinoma: incidence, risk factors and prognostic value. HPB (Oxford) 18:540–548
doi: 10.1016/j.hpb.2016.04.004
Wu G, Zhang DY, Duan YH et al (2017) Correlations of hemoglobin level and perioperative blood transfusion with the prognosis of gastric cancer: a retrospective study. Med Sci Monit 23:2470–2478
doi: 10.12659/MSM.900907
Huang XZ, Yang YC, Chen Y et al (2019) Preoperative anemia or low hemoglobin predicts poor prognosis in gastric cancer patients: a meta-analysis. Dis Markers 2019:7606128
pubmed: 30719182
pmcid: 6334363
Kaya A, Kurt M, Tanboga IH (2014) Neutrophil-to-lymphocyte ratio predicts contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology 65:59
doi: 10.1177/0003319713502847
Kocas C, Yildiz A, Abaci O et al (2015) Platelet-to-lymphocyte ratio predicts contrast-induced nephropathy in patients with non-ST-segment elevation acute coronary syndrome. Angiology 66:964–968
doi: 10.1177/0003319715578057
Yuan Y, Qiu H, Hu X et al (2017) Predictive value of inflammatory factors on contrast-induced acute kidney injury in patients who underwent an emergency percutaneous coronary intervention. Clin Cardiol 40:719–725
doi: 10.1002/clc.22722
Kong T, Park YS, Lee HS et al (2018) A delta neutrophil index for the prediction of contrast-induced nephropathy in patients with St-elevation myocardial infarction followed by percutaneous coronary intervention. Shock 49:317–325
doi: 10.1097/SHK.0000000000000957
Sun XP, Li J, Zhu WW et al (2018) Platelet to lymphocyte ratio predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology 69:71–78
doi: 10.1177/0003319717707410
Jiang J, Ji HY, Xie WM et al (2019) Could platelet-to-lymphocyte ratio be a predictor for contrast-induced nephropathy in patients with acute coronary syndrome?: A systematic review and meta-analysis. Medicine (Baltimore) 98:e16801
doi: 10.1097/MD.0000000000016801
Satilmis S, Karabulut A (2020) Value of C-reactive protein/albumin ratio in predicting the development of contrast-induced nephropathy in patients with non-ST elevation myocardial infarction. Angiology 71(4):366–371
doi: 10.1177/0003319719898057
Zorlu C, Koseoglu C (2020) Comparison of the relationship between inflammatory markers and contrast-induced nephropathy in patients with acute coronary syndrome after coronary angiography. Angiology 71:249–255
doi: 10.1177/0003319719892160
Hossain MA, Costanzo E, Cosentino J et al (2018) Contrast-induced nephropathy: pathophysiology, risk factors, and prevention. Saudi J Kidney Dis Transpl 29:1–9
doi: 10.4103/1319-2442.225199
van der Molen AJ, Reimer P, Dekkers IA et al (2018b) Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 28:2856–2869
doi: 10.1007/s00330-017-5247-4
Zhang J, Guo Y, Jin Q et al (2018) Meta-analysis of rosuvastatin efficacy in prevention of contrast-induced acute kidney injury. Drug Des Devel Ther 12:3685–3690
doi: 10.2147/DDDT.S178020
Klause N, Arendt T, Lins M et al (1998) Hypoxic renal tissue damage by endothelin-mediated arterial vasoconstriction during radioangiography in man. Adv Exp Med Biol 454:225–234
doi: 10.1007/978-1-4615-4863-8_27
Abu Jawdeh BG, Leonard AC, Sharma Y et al (2017) Contrast-induced nephropathy in renal transplant recipients: a single center experience. Front Med (Lausanne) 4:64
doi: 10.3389/fmed.2017.00064
Kim SJ, Salem MR, Joseph NJ et al (1990) Contrast media adversely affect oxyhemoglobin dissociation. Anesth Analg 71:73–76
doi: 10.1213/00000539-199007000-00013
Nurko S (2006) Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleve Clin J Med 73:289–297
doi: 10.3949/ccjm.73.3.289
Weiss G, Ganz T, Goodnough LT (2019) Anemia of inflammation. Blood 133:40–50
doi: 10.1182/blood-2018-06-856500
Sreenivasan J, Zhuo M, Khan MS et al (2018) Anemia (Hemoglobin </= 13 g/dL) as a risk factor for contrast-induced acute kidney injury following coronary angiography. Am J Cardiol 122:961–965
doi: 10.1016/j.amjcard.2018.06.012